MiniMed™ 780G system

MiniMed 780G System More control,
less effort

For people living with Type 1 diabetes

MiniMed™ 780G System Apple Watch

Minimed 780G System with SmartGuard™ technology

Our most advanced insulin pump system with SmartGuard™ automation for self-adjusting basal delivery with autocorrection dosing. 

Now with Guardian™ 4 sensor.

NEW! Now compatible with Apple® Watch

Enya
Play button
I’m a very sporty person and I play Gaelic netball and dancing, and I think the pump is amazing to do those sports because it always keeps your bloods in range

Enya is 13 years old, from Republic of Ireland.
MiniMed 780G user

Automatically  adjusts insulin delivery and corrects glucose levels every 5 minutes, 24/7
with no finger pricks 

Corrects

Automatically  corrects highs to help for undercounted carbs or an occasionally missed meal dose1

Adjusts

Makes precise adjustments of insulin delivery to help protect from highs and lows.

Anticipates

Monitors insulin needs based on real-time glucose levels and personal trends. 

Learn more about
the MiniMed™ 780G System.

Learn more

References

  1. Carlson AL, et al. Diab Tech and Therap. 2021; DOI 10.1089/dia.2021.0319
  2. Collyns OJ, et al. Diabetes Care. 2021;44(4):969-975.
  3. Medtronic data on file: MiniMed ™ 780G data uploaded voluntarily by 12.870 users in EMEA to CareLink™ Personal, from 27 August 2020 to 22 July 2021. Mean 80% TIR reached by 1.784 users using MiniMed ™ 780G with recommended settings of 2 hours active insulin time and 100 mg/dL (5.5 mmol/L) as glucose target for at least 90% of the time.
  4. Battelino T, et al. Diabetes Care 2019; 42(8): 1593-1603.
  5. Medtronic data on file: MiniMed™ 780G users survey conducted in April-May 2021 in UK, Sweden, Italy, Netherlands and Belgium. Sample size = 789.
  6. Medtronic data on file. MRM 17430 MiniMed™ Mio™ Advance claims from Human Factors Testing.
  7. Medtronic data on File IFU Comparison versus MiniMed™ Quick Set.
  8. ADA. 6. Glycemic Targets: Standards of Medical Care in Diabetes—2022 Diabetes Care 2022;45(Suppl. 1): S83–S96
  9. Zhang G, et al. 986-P at the 80th ADA International Conference, June 2020.
  10. Ilany J, et al. Abstract 416 at the 13th ATTD International Conference. February 2020.
  • 1.Carlson AL, et al. Diab Tech and Therap. 2021; DOI 10.1089/dia.2021.0319
  • 1.Carlson AL, et al. Diab Tech and Therap. 2021; DOI 10.1089/dia.2021.0319
  • 2.Collyns OJ, et al. Diabetes Care. 2021;44(4):969-975.
  • 1.Carlson AL, et al. Diab Tech and Therap. 2021; DOI 10.1089/dia.2021.0319
  • 2.Collyns OJ, et al. Diabetes Care. 2021;44(4):969-975.
  • 3.Medtronic data on file: MiniMed ™ 780G data uploaded voluntarily by 12.870 users in EMEA to CareLink™ Personal, from 27 August 2020 to 22 July 2021. Mean 80% TIR reached by 1.784 users using MiniMed ™ 780G with recommended settings of 2 hours active insulin time and 100 mg/dL (5.5 mmol/L) as glucose target for at least 90% of the time.
  • 3.Medtronic data on file: MiniMed ™ 780G data uploaded voluntarily by 12.870 users in EMEA to CareLink™ Personal, from 27 August 2020 to 22 July 2021. Mean 80% TIR reached by 1.784 users using MiniMed ™ 780G with recommended settings of 2 hours active insulin time and 100 mg/dL (5.5 mmol/L) as glucose target for at least 90% of the time.
  • 4.Battelino T, et al. Diabetes Care 2019; 42(8): 1593-1603.
  • 5.Medtronic data on file: MiniMed™ 780G users survey conducted in April-May 2021 in UK, Sweden, Italy, Netherlands and Belgium. Sample size = 789.
  • 6.Medtronic data on file. MRM 17430 MiniMed™ Mio™ Advance claims from Human Factors Testing.
  • 6.Medtronic data on file. MRM 17430 MiniMed™ Mio™ Advance claims from Human Factors Testing.
  • 7.Medtronic data on File IFU Comparison versus MiniMed™ Quick Set.
  • 9.Zhang G, et al. 986-P at the 80th ADA International Conference, June 2020.
  • 10.Ilany J, et al. Abstract 416 at the 13th ATTD International Conference. February 2020.
  • 1.Carlson AL, et al. Diab Tech and Therap. 2021; DOI 10.1089/dia.2021.0319
  • 3.Medtronic data on file: MiniMed™ 780G data uploaded voluntarily by 12.870 users in EMEA to CareLink™ Personal, from 27 August 2020 to 22 July 2021. Mean 80% TIR reached by 1.784 users using MiniMed ™ 780G with recommended settings of 2 hours active insulin time and 100 mg/dL (5.5 mmol/L) as glucose target for at least 90% of the time.
  • 4.Battelino T, et al. Diabetes Care 2019; 42(8): 1593-1603.
  • 8.ADA. 6. Glycemic Targets: Standards of Medical Care in Diabetes—2022 Diabetes Care 2022;45(Suppl. 1): S83–S96
  • * Refer to System User Guide - SmartGuard™ feature. Some user interaction required.
  • ** Glucose Management Indicator (GMI) data from CGM values were used to estimate HbA1c. Calculated using JAEB https://www.jaeb.org/gmi/.
  • *** Compared with the MiniMed™ 670G system.
  • † A blood glucose (BG) reading is needed when entering SmartGuard™ feature. If glucose alerts and CGM readings do not match your symptoms, use a BG meter to make diabetes treatment decisions. Refer to System User Guide - SmartGuard™ feature. Some user interaction required.
  • †† Refer to MiniMed™ Mobile app. User Guide
  • ††† At the time of manufacture and when the reservoir and tubing are properly inserted, your pump is waterproof.
  • # Multiple Daily Injections (3 bolus and 1 basal insulin per day) requires 28 injections per week vs. one infusion set change every two to three days.
  • ## Versus SAP+PLGM or pre-AHCL initiation.
  • ### vs the 3-day infusion set MiniMed™ Quick-set™
  • ~ Refer to Accu-Chek® Guide Link User's Manual
  • * Refer to System User Guide - SmartGuard™ feature. Some user interaction required.
  • † A blood glucose (BG) reading is needed when entering SmartGuard™ feature. If glucose alerts and CGM readings do not match your symptoms, use a BG metre to make diabetes treatment decisions. Refer to System User Guide - SmartGuard™ feature. Some user interaction required.
  • 10.Ilany J, et al. Abstract 416 at the 13th ATTD International Conference. February 2020.
  • ~ Refer to Accu-Chek® Guide Link User's Manual
  • 99% of people who previously used Multiple Daily Injections with isCGM/CGM therapy, agreed that the MiniMed™ 780G insulin pump system was better
  • For illustrative purposes only.

All clinical data and surveys results included in this document refer to MiniMed™ 780G system used in combination with Guardian™ sensor 3. Information contained herein is not medical advice and should not be used as an alternative to speaking with your doctor. Discuss indications, contraindications, warnings, precautions, potential adverse events and any further information with your health care professional.

UK-IPT-2300128©2023 Medtronic. All rights reserved Medtronic. Medtronic logo and Further, Together are trademarks of Medtronic. Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company. ACCU-CHEK AND ACCU-CHEK GUIDE LINK are trademarks of Roche Diabetes Care. DreaMed Diabetes is a trademark of DreaMed Diabetes. Ltd. The MiniMed™ 780G system algorithm includes technology developed by DreaMed Diabetes. The legal manufacturer of MiniMed™ Mio ™ Advance infusion set is Unomedical a/s. Aaholmvej 1-3, Osted. 4320 Lejre, Denmark.